产品
编 号：F752061
分子式：C28H28D5N7O2
分子量：504.64
分子式：C28H28D5N7O2
分子量：504.64
产品类型
规格
价格
是否有货
结构图
CAS No: 2403760-70-1
产品详情
生物活性：
Dosimertinib-d3-d3 is a potent and orally active EGFR inhibitor. Dosimertinib-d3-d3 decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d3-d3 shows antiproliferative and anti-tumor activity. Dosimertinib-d3-d3 has the potential for the research of non-small-cell lung cancer (NSCLC).
体内研究：
Dosimertinib (0.75、1.5、3 mg/kg；口服，每天一次，持续 24 天) 在小鼠体内显示出抗肿瘤活性。Animal Model:18-20 g, BALB/c nude mice (H1975 mouse xenograft model)
Dosage:0.75, 1.5, 3 mg/kg
Administration:Oral gavage; daily for 24 days
Result:Significantly reduced tumor size with tumor growth inhibition (TGI) of 72.94% and 97.62% at 1.5, 3 mg/kg, respectively.
体外研究：
Dosimertinib (compound 2h) (1, 10, 100, 100 nM; 2h) 以剂量依赖性方式降低 p-EGFR 和 p-ERK 蛋白水平。
Dosimertinib-d3-d3 is a potent and orally active EGFR inhibitor. Dosimertinib-d3-d3 decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d3-d3 shows antiproliferative and anti-tumor activity. Dosimertinib-d3-d3 has the potential for the research of non-small-cell lung cancer (NSCLC).
体内研究：
Dosimertinib (0.75、1.5、3 mg/kg；口服，每天一次，持续 24 天) 在小鼠体内显示出抗肿瘤活性。Animal Model:18-20 g, BALB/c nude mice (H1975 mouse xenograft model)
Dosage:0.75, 1.5, 3 mg/kg
Administration:Oral gavage; daily for 24 days
Result:Significantly reduced tumor size with tumor growth inhibition (TGI) of 72.94% and 97.62% at 1.5, 3 mg/kg, respectively.
体外研究：
Dosimertinib (compound 2h) (1, 10, 100, 100 nM; 2h) 以剂量依赖性方式降低 p-EGFR 和 p-ERK 蛋白水平。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备